Drug Profile
Cantuzumab ravtansine
Alternative Names: C-242 DM4; C242 DM4 immunoconjugate; C242 maytansinoid-4 conjugate; huC242-DM4; IMGN-242; Maytasinoid DM4-conjugated humanised monoclonal antibody huC242; Monoclonal antibody C-242 DM4 conjugateLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastric cancer; Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 12 Jun 2009 Discontinued - Phase-I for Solid tumours in USA (IV)
- 12 Jun 2009 Discontinued - Phase-II for Gastric cancer in USA (IV)